Text this: THREE YEARS' EXPERIENCE WITH THE BIOLOGICAL AGENT DENOSUMAB USED TO TREAT WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS: EFFICACY, SAFETY AND TREATMENT ADHERENCE